Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best doses of RAD001 (everolimus) tablets and
cisplatin to give to patients who are receiving radiation therapy for head and neck cancer.